This adds to a series of recent pipeline cuts, potentially impacting investor confidence. Looking ahead, the company is placing increased importance on upcoming trial results, particularly the Phase 3 ...

Looking ahead, the company is placing increased importance on upcoming trial results, particularly the Phase 3 readout for dapirolizumab pegol in Systemic Lupus Erythematosus (SLE). The success of ...

This adds to a series of recent pipeline cuts, potentially impacting investor confidence. Looking ahead, the company is placing increased importance on upcoming trial results, particularly the Phase 3 ...

along with other late-stage programmes like Sage Therapeutics-partnered antidepressant zuranolone, lupus therapies litifilimab and dapirolizumab pegol, and stroke candidate BIIB093.

Steroid Use in SLE Half of lupus patients taking dapirolizumab pegol achieved response at week 48 compared with one third of patients taking placebo. Medscape Medical News, November 25 ...